Enbrel is also known as butylphthalide softgels. Its indications are mainly for the treatment of mild to moderate acute ischemic stroke. Its pathological effects are mainly to reduce intracellular Ca ion concentration, inhibit glutamate release, reduce arachidonic acid production, scavenge oxygen free radicals, and increase antioxidant enzyme activity, which act on multiple pathological aspects of cerebral ischemia. It can significantly improve microcirculation and blood flow in the cerebral ischemic area, while increasing the number of capillaries in the cerebral ischemic area, reducing cerebral edema, reducing the size of cerebral infarction, improving cerebral energy metabolism, reducing neural cell apoptosis, and inhibiting thrombus formation. Enbep has a clear therapeutic effect on ischemic cerebrovascular disease and can promote the recovery of damaged neurological functions of patients.